Meropenem


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: IV> Susceptible gram-positive infections; Susceptible gram-negative infections In cases of severe pneumonia, complicated UTI, complicated intra-abdominal infections, complicated skin and skin structure infections, gynaecological infections: 0.5-1 g 8 hourly via infusion over approx 15-30 minutes or via bolus inj over approx 3-5 minutes. Exacerbation of respiratory tract infections in cystic fibrosis; Bacterial meningitis 2 g 8 hourly via infusion over approx 15-30 minutes.
Contraindications
Hypersensitivity to meropenem or other carbapenems. History of anaphylactic reaction to β-lactams (e.g. penicillins, cephalosporins).
Special Precautions
Patient with CNS disorder (e.g. brain lesions, history of seizures). Renal and hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause seizure, headache, paraesthesia, and delirium, if affected, do not drive or operate machinery. Monitoring Parameters Perform culture and sensitivity testing prior to initiation of therapy. Monitor renal function, LFT, CBC (prolonged use). Monitor for signs of anaphylaxis during 1st dose.
Adverse Reactions
Significant: Confusional states and seizure; severe cutaneous reactions (e.g. Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], drug reaction with eosinophilia and systemic symptoms [DRESS], erythema multiforme, acute generalised exanthematous pustulosis); fungal or bacterial superinfection including C. difficile-associated diarrhoea. Blood and lymphatic system disorders: Thrombocythaemia, anaemia. Gastrointestinal disorders: Diarrhoea, vomiting, nausea, abdominal pain, constipation. General disorders and administration site conditions: Injection site inflammation, pain. Investigations: Increased transaminases, increased alkaline phosphatase, increased lactate dehydrogenase. Nervous system disorders: Headache. Skin and subcutaneous tissue disorders: Rash, pruritus.
Potentially Fatal: Hypersensitivity reactions (e.g. anaphylaxis), antibiotic-associated or pseudomembranous colitis.
Drug Interactions
Increased plasma concentration and prolonged elimination half-life with probenecid. May decrease plasma levels of valproic acid, thus increasing the risk of seizures. May enhance anticoagulant effect of warfarin.
CIMS Class
ATC Classification
J01DH02 - meropenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on meropenem from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in